Janssen Reports P-III Study (CARTITUDE-4) Results of Carvykti (cilta-cel) for the Treatment of Multiple Myeloma
Shots:
- The P-III study (CARTITUDE-4) that evaluated the efficacy & safety of Carvykti vs pomalidomide, bortezomib & dexamethasone (PVd), or daratumumab, pomalidomide & dexamethasone (DPd) in patients with r/r MM who received one to three prior lines of therapy
- The trial met its 1EPs i.e., improvement in PFS at the first pre-specified interim analysis. Based on the positive results, the IDMC recommended the unblinding of the P-III study & the results will be shared with health authorities
- The therapy was approved in the US in Feb 2022 for r/r MM & received conditional marketing authorization from EC in May 2022. The therapy was also approved in Japan in Sept 2022 for the same indication
Ref: PRNewswire | Image: Janssen
Related Post: Janssen Presents Efficacy and Subgroup Analyses from P-III Study (MAIA) Results of Darzalex for Multiple Myeloma at ASH 2022
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
